D-0674-2026 Class II Ongoing

Recalled by Reliance Life Sciences Private Limited — Navi Mumbai, N/A

FDA drug recall D-0674-2026 was initiated by Reliance Life Sciences Private Limited on Jun 24, 2026 and is designated Class II. Reason for recall: Lack of Sterility Assurance The recall status is ongoing. Affected quantity: 8,001 vials.

Recall details

Product Type
Drugs
Report Date
Jul 15, 2026
Initiation Date
Jun 24, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
8,001 vials

Product description

Azacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For Subcutaneous and Intravenous Use, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873 NDC: 70069-0857-01

Reason for recall

Lack of Sterility Assurance

Distribution pattern

Nationwide in the USA

Code information

Lot, expiry: RAZM0425A Jun 30, 2027; RAZM0525A Jun 30, 2027; RAZM0725A Jun 30, 2027; RAZM0825A Jun 30, 2027; RAZM0925A Jul 31, 2027; RAZM1125A Jul 31, 2027; RAZM1225A Jul 31, 2027; RAZM1425A Jul 31, 2027; RAZM1525A Jul 31, 2027; RAZM1625A Aug 31, 2027; RAZM1725A Aug 31, 2027; RAZM2025A Sep 30, 2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0674-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0674-2026. Report a data issue: hello@regdatalab.com.